Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-072125
Filing Date
2025-05-15
Accepted
2025-05-15 11:05:50
Documents
4

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 17024
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 33505
3 EX-99.2 ck0001669811-ex99_2.pdf EX-99.2 34794
4 EX-99.3 ck0001669811-ex99_3.pdf EX-99.3 113890
  Complete submission text file 0000950170-25-072125.txt   270796
Mailing Address 1099 AMERIPRISE FINANCIAL CENTER MINNEAPOLIS MN 55474
Business Address 1099 AMERIPRISE FINANCIAL CENTER MINNEAPOLIS MN 55474 612-671-8001
AMERIPRISE FINANCIAL INC (Filed by) CIK: 0000820027 (see all company filings)

EIN.: 133180631 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6282 Investment Advice
(CF Office: 02 Finance)

Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Subject) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-80900 | Film No.: 25950030
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)